Johnson & Johnson - JNJ Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $189.78
  • Forecasted Upside: 17.16 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$161.98
▼ -1.38 (-0.84%)

This chart shows the closing price for JNJ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Johnson & Johnson Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JNJ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JNJ

Analyst Price Target is $189.78
▲ +17.16% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Johnson & Johnson in the last 3 months. The average price target is $189.78, with a high forecast of $205.00 and a low forecast of $173.00. The average price target represents a 17.16% upside from the last price of $161.98.

This chart shows the closing price for JNJ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in Johnson & Johnson. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/4/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/2/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/2/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/12/2022Morgan StanleyLower TargetEqual Weight$174.00 ➝ $173.00Low
7/21/2022UBS GroupLower Target$185.00 ➝ $180.00Low
7/20/2022SVB LeerinkLower Target$200.00 ➝ $194.00Low
7/20/2022CitigroupLower Target$205.00 ➝ $201.00Low
7/13/2022Wells Fargo & CompanyBoost TargetOverweight$190.00 ➝ $195.00N/A
7/8/2022Morgan StanleyBoost TargetEqual Weight$173.00 ➝ $174.00N/A
6/22/2022Daiwa Capital MarketsInitiated CoverageOutperformLow
5/17/2022CitigroupLower Target$210.00 ➝ $205.00N/A
4/20/2022Raymond JamesBoost TargetOutperform$195.00 ➝ $196.00Low
4/20/2022Credit Suisse GroupBoost TargetOutperform$200.00 ➝ $205.00Low
4/20/2022CitigroupBoost TargetBuy$203.00 ➝ $210.00Low
4/14/2022Raymond JamesBoost TargetOutperform$185.00 ➝ $195.00Low
4/12/2022The Goldman Sachs GroupBoost TargetNeutral$163.00 ➝ $181.00Low
4/6/2022Morgan StanleyLower TargetEqual Weight$175.00 ➝ $173.00High
3/16/2022Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$180.00 ➝ $183.00Low
3/2/2022Bank of AmericaInitiated CoverageNeutral ➝ NeutralLow
1/26/2022Raymond JamesBoost Target$178.00 ➝ $185.00Low
1/24/2022Morgan StanleyLower TargetEqual Weight$187.00 ➝ $175.00Medium
12/17/2021The Goldman Sachs GroupInitiated CoverageNeutral$161.00High
12/15/2021CitigroupReiterated RatingBuy ➝ Buy$192.00 ➝ $195.00Low
10/20/2021Raymond JamesLower TargetOutperform$183.00 ➝ $178.00Low
10/7/2021Wells Fargo & CompanyReiterated RatingBuyLow
9/7/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$187.00Medium
7/29/2021SVB LeerinkReiterated RatingBuyLow
7/21/2021SVB LeerinkReiterated RatingOutperformLow
6/7/2021Credit Suisse GroupSet TargetBuy$193.00Low
6/1/2021Credit Suisse GroupSet TargetBuy$193.00High
5/28/2021Morgan StanleyInitiated CoverageOverweight$187.00Low
1/27/2021JPMorgan Chase & Co.Boost TargetNeutral$157.00 ➝ $175.00Medium
1/27/2021Credit Suisse GroupBoost TargetOutperform$168.00 ➝ $193.00Medium
1/27/2021Raymond JamesBoost TargetOutperform$158.00 ➝ $183.00Medium
1/27/2021CowenBoost TargetOutperform$170.00 ➝ $195.00Medium
1/27/2021Morgan StanleyBoost TargetOverweight$178.00 ➝ $187.00Medium
1/27/2021SVB LeerinkBoost TargetOutperform$180.00 ➝ $200.00Medium
1/27/2021Wells Fargo & CompanyBoost TargetPositive ➝ Overweight$175.00 ➝ $190.00Medium
1/26/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$180.00 ➝ $200.00Medium
12/15/2020Morgan StanleyBoost TargetOverweight$170.00 ➝ $178.00Low
11/20/2020Raymond JamesReiterated RatingBuyMedium
10/14/2020Credit Suisse GroupBoost TargetPositive ➝ Outperform$163.00 ➝ $168.00Low
10/14/2020Cantor FitzgeraldBoost TargetPositive ➝ Overweight$168.00 ➝ $180.00Low
10/13/2020Credit Suisse GroupSet TargetBuy$163.00Low
9/4/2020Credit Suisse GroupReiterated RatingBuyMedium
8/19/2020Stifel NicolausDowngradeBuy ➝ HoldLow
8/3/2020Cantor FitzgeraldReiterated RatingBuy$168.00Low
7/20/2020Bank of AmericaReiterated RatingBuyLow
7/20/2020Independent ResearchUpgradeHold ➝ Buy$161.00 ➝ $164.00Low
7/17/2020Raymond JamesBoost TargetOutperform$157.00 ➝ $158.00Medium
7/17/2020CitigroupBoost TargetBuy$165.00 ➝ $170.00Low
7/15/2020SVB LeerinkReiterated RatingOutperformMedium
4/29/2020Morgan StanleyBoost TargetOverweight$160.00 ➝ $170.00Low
4/29/2020BarclaysBoost TargetOverweight$173.00 ➝ $182.00Low
4/28/2020Cantor FitzgeraldReiterated RatingBuy$168.00Low
4/28/2020Credit Suisse GroupReiterated RatingBuy$161.00Low
4/28/2020UBS GroupDowngradeBuy ➝ Neutral$163.00 ➝ $160.00Medium
4/22/2020Wells Fargo & CompanyUpgradeHoldMedium
4/22/2020Bank of AmericaUpgradeNeutral ➝ Buy$150.00 ➝ $175.00Low
4/15/2020Stifel NicolausBoost TargetHold$140.00 ➝ $155.00Medium
4/15/2020Wells Fargo & CompanyBoost TargetOverweight$150.00 ➝ $162.00Medium
4/15/2020CitigroupBoost TargetBuy$150.00 ➝ $165.00Medium
4/15/2020Raymond JamesBoost TargetOutperform$153.00 ➝ $157.00Low
4/15/2020Credit Suisse GroupBoost TargetOutperform$155.00 ➝ $161.00Low
4/9/2020Raymond JamesLower TargetOutperform$161.00 ➝ $153.00Low
4/8/2020SVB LeerinkLower TargetOutperform$172.00 ➝ $160.00High
4/3/2020Cantor FitzgeraldReiterated RatingBuy$168.00High
4/2/2020Wells Fargo & CompanyLower TargetOverweight$165.00 ➝ $150.00Medium
4/1/2020Stifel NicolausLower TargetHold$155.00 ➝ $140.00Low
3/27/2020Morgan StanleyLower TargetOverweight$170.00 ➝ $160.00Medium
3/27/2020CitigroupLower TargetBuy$163.00 ➝ $150.00Low
3/27/2020ArgusReiterated RatingBuy$165.00 ➝ $155.00Low
3/6/2020Credit Suisse GroupLower TargetOutperform$170.00 ➝ $159.00Medium
3/4/2020CitigroupInitiated CoverageBuy$163.00Low
2/17/2020Credit Suisse GroupReiterated RatingBuy$170.00Medium
1/27/2020Credit Suisse GroupBoost TargetOutperform$163.00 ➝ $170.00Low
1/23/2020Cantor FitzgeraldReiterated RatingBuy$168.00Low
1/23/2020Raymond JamesBoost TargetOutperform$147.00 ➝ $161.00Low
1/9/2020Wells Fargo & CompanyBoost TargetOverweight$155.00 ➝ $165.00Low
12/31/2019Credit Suisse GroupReiterated RatingBuy$163.00Low
12/19/2019BarclaysUpgradeEqual Weight ➝ Overweight$140.00 ➝ $173.00Medium
12/17/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$145.00 ➝ $170.00Low
11/27/2019Cantor FitzgeraldInitiated CoverageOverweight$160.00Low
11/19/2019Cantor FitzgeraldInitiated CoverageOverweight$160.00 ➝ $160.00Low
10/24/2019Credit Suisse GroupBoost Target$158.00 ➝ $163.00Low
10/16/2019Credit Suisse GroupBoost TargetOutperform$156.00 ➝ $158.00Medium
10/16/2019Wells Fargo & CompanyLower TargetOutperform$157.00 ➝ $155.00Medium
10/16/2019Atlantic SecuritiesUpgradeUnderweight ➝ NeutralMedium
10/14/2019Raymond JamesLower TargetOutperform$146.00 ➝ $145.00Low
10/11/2019Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$155.00Low
8/27/2019The Goldman Sachs GroupSet TargetBuy$169.00Medium
8/27/2019Morgan StanleyReiterated RatingEqual Weight$145.00High
8/27/2019Credit Suisse GroupSet TargetBuy$156.00Low
7/18/2019Credit Suisse GroupSet TargetBuy$156.00Low
7/17/2019Raymond JamesLower TargetOutperform$147.00 ➝ $146.00Low
7/16/2019Royal Bank of CanadaReiterated RatingBuyLow
7/16/2019Bank of AmericaReiterated RatingHold$150.00Low
7/12/2019Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$156.00High
6/21/2019BarclaysInitiated CoverageHold$140.00Low
5/28/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ BuyHigh
5/16/2019Credit Suisse GroupBoost TargetOutperform$152.00 ➝ $156.00Low
5/6/2019Wells Fargo & CompanyReiterated RatingOutperform$152.00 ➝ $157.00Low
4/17/2019BMO Capital MarketsBoost TargetOutperform ➝ Outperform$154.00 ➝ $157.00Low
4/17/2019Credit Suisse GroupBoost TargetOutperform ➝ Outperform$151.00 ➝ $152.00Low
4/17/2019Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$134.00 ➝ $145.00Low
4/17/2019Raymond JamesBoost TargetOutperform ➝ Outperform$145.00 ➝ $147.00Low
2/25/2019CitigroupBoost TargetNeutral ➝ Neutral$139.00 ➝ $147.00Low
1/23/2019BarclaysReiterated RatingEqual Weight ➝ Equal Weight$137.00 ➝ $135.00High
1/14/2019Wells Fargo & CompanyReiterated RatingOutperform ➝ Outperform$162.00 ➝ $152.00Low
1/2/2019Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$153.00 ➝ $130.00Low
1/2/2019CitigroupLower TargetNeutral ➝ Neutral$148.00 ➝ $139.00Low
12/20/2018Morgan StanleySet TargetHold$140.00Low
10/22/2018CitigroupBoost TargetNeutral ➝ Neutral$137.00 ➝ $148.00Low
10/17/2018Credit Suisse GroupBoost TargetOutperform ➝ Outperform$149.00 ➝ $152.00Medium
10/17/2018Raymond JamesBoost TargetOutperform ➝ Outperform$144.00 ➝ $149.00Medium
10/17/2018Wells Fargo & CompanyReiterated RatingOutperform$155.00 ➝ $160.00Medium
10/17/2018HC WainwrightReiterated RatingBuyHigh
10/14/2018Credit Suisse GroupSet TargetBuy$149.00Low
9/14/2018Wells Fargo & CompanyReiterated RatingOutperform$160.00Low
7/15/2018Jefferies Financial GroupSet TargetBuy$145.00Medium
7/13/2018Credit Suisse GroupSet TargetBuy$151.00Medium
7/12/2018The Goldman Sachs GroupUpgradeSell ➝ NeutralLow
6/27/2018Sanford C. BernsteinInitiated CoverageMarket Perform$129.00Low
6/12/2018Credit Suisse GroupSet TargetBuy$151.00Low
4/23/2018CitigroupLower TargetNeutral$146.00 ➝ $134.00Low
4/20/2018Credit Suisse GroupLower TargetOutperform ➝ Outperform$154.00 ➝ $151.00Low
4/18/2018Wells Fargo & CompanyReiterated RatingOutperform$160.00 ➝ $150.00High
4/18/2018Stifel NicolausLower TargetHold ➝ Hold$145.00 ➝ $135.00High
4/18/2018SVB LeerinkReiterated RatingOutperform$175.00 ➝ $160.00High
4/18/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyHigh
4/17/2018Credit Suisse GroupSet TargetBuy$154.00High
4/17/2018The Goldman Sachs GroupSet TargetSell$134.00Low
4/13/2018Jefferies Financial GroupSet TargetBuy$153.00Low
4/10/2018Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$148.00 ➝ $143.00Low
3/23/2018Jefferies Financial GroupSet TargetBuy$161.00Medium
2/27/2018CitigroupLower TargetNeutral ➝ Neutral$150.00 ➝ $146.00Medium
2/26/2018Jefferies Financial GroupSet TargetBuy$165.00Low
1/24/2018Stifel NicolausBoost TargetHold ➝ Hold$142.00 ➝ $145.00Low
1/24/2018BTIG ResearchReiterated RatingSell$110.00Low
1/22/2018Credit Suisse GroupSet TargetHold$154.00High
1/12/2018Wells Fargo & CompanyReiterated RatingOutperform ➝ Outperform$155.00 ➝ $160.00Low
1/9/2018Royal Bank of CanadaReiterated RatingBuyLow
1/2/2018JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
12/12/2017BMO Capital MarketsBoost TargetOutperform$161.00Medium
10/23/2017CitigroupBoost TargetBuy$140.00 ➝ $149.00N/A
10/19/2017Credit Suisse GroupSet TargetOutperform$147.00 ➝ $154.00N/A
10/18/2017BarclaysBoost TargetEqual Weight$140.00 ➝ $148.00N/A
10/18/2017CowenReiterated RatingOutperform$147.00 ➝ $155.00N/A
10/18/2017Morgan StanleyReiterated RatingHold$140.00 ➝ $145.00N/A
10/18/2017ArgusBoost TargetBuy ➝ Positive$145.00 ➝ $165.00N/A
10/18/2017Wells Fargo & CompanyReiterated RatingOutperform$149.00 ➝ $155.00N/A
10/18/2017BMO Capital MarketsReiterated RatingOutperform ➝ Positive$145.00 ➝ $152.00N/A
10/18/2017Stifel NicolausBoost TargetHold ➝ Hold$140.00 ➝ $142.00N/A
10/18/2017Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$144.00 ➝ $147.00N/A
10/18/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$150.00 ➝ $165.00N/A
10/16/2017Jefferies Financial GroupBoost TargetBuy$157.00 ➝ $160.00N/A
10/11/2017Jefferies Financial GroupUpgradeHold ➝ Buy$145.00 ➝ $157.00N/A
10/9/2017Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$140.00 ➝ $149.00N/A
10/6/2017CowenSet TargetBuy$147.00N/A
10/4/2017Piper Jaffray CompaniesReiterated RatingHold$120.00Low
(Data available from 10/3/2017 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 24 very positive mentions
  • 50 positive mentions
  • 13 negative mentions
  • 16 very negative mentions
3/7/2022
  • 20 very positive mentions
  • 23 positive mentions
  • 5 negative mentions
  • 6 very negative mentions
4/6/2022
  • 25 very positive mentions
  • 60 positive mentions
  • 14 negative mentions
  • 12 very negative mentions
5/6/2022
  • 16 very positive mentions
  • 32 positive mentions
  • 9 negative mentions
  • 3 very negative mentions
6/5/2022
  • 28 very positive mentions
  • 37 positive mentions
  • 6 negative mentions
  • 5 very negative mentions
7/5/2022
  • 32 very positive mentions
  • 64 positive mentions
  • 13 negative mentions
  • 7 very negative mentions
8/4/2022
  • 16 very positive mentions
  • 38 positive mentions
  • 18 negative mentions
  • 18 very negative mentions
9/3/2022
  • 21 very positive mentions
  • 33 positive mentions
  • 9 negative mentions
  • 8 very negative mentions
10/3/2022

Current Sentiment

  • 21 very positive mentions
  • 33 positive mentions
  • 9 negative mentions
  • 8 very negative mentions

Recent Stories by Sentiment

Johnson & Johnson logo
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Read More

Today's Range

Now: $161.98
Low: $161.77
High: $164.82

50 Day Range

MA: $167.13
Low: $161.33
High: $174.59

52 Week Range

Now: $161.98
Low: $155.72
High: $186.69

Volume

286,838 shs

Average Volume

7,492,113 shs

Market Capitalization

$425.87 billion

P/E Ratio

23.58

Dividend Yield

2.77%

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Johnson & Johnson?

The following Wall Street sell-side analysts have issued research reports on Johnson & Johnson in the last twelve months: Bank of America Co., Citigroup Inc., Credit Suisse Group AG, Daiwa Capital Markets, Morgan Stanley, Raymond James, Sanford C. Bernstein, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for JNJ.

What is the current price target for Johnson & Johnson?

9 Wall Street analysts have set twelve-month price targets for Johnson & Johnson in the last year. Their average twelve-month price target is $189.78, suggesting a possible upside of 16.2%. Credit Suisse Group AG has the highest price target set, predicting JNJ will reach $205.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $173.00 for Johnson & Johnson in the next year.
View the latest price targets for JNJ.

What is the current consensus analyst rating for Johnson & Johnson?

Johnson & Johnson currently has 4 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe JNJ will outperform the market and that investors should add to their positions of Johnson & Johnson.
View the latest ratings for JNJ.

What other companies compete with Johnson & Johnson?

How do I contact Johnson & Johnson's investor relations team?

Johnson & Johnson's physical mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company's listed phone number is (732) 524-0400. The official website for Johnson & Johnson is www.jnj.com. Learn More about contacing Johnson & Johnson investor relations.